While U.S. consumers are exposed to constant messaging about peptides, a new report reveals many are still confused about what the therapies are.
Industry leaders pointed to fitness' ability to drive stronger healthcare and social wellness outcomes as key levers for the industry's future. The rise of GLP-1s offers another opportunity, they said.
Xenom held its inaugural “decathlon of fitness” competition in Frisco, Texas, this past weekend. The new event isn't coming for Hyrox, but it does share similarities with CrossFit.
Fitbit data from 750 adults found that daily movement and exercise levels declined after people started taking GLP-1 weight-loss drugs.
NASM data shows personal trainers are expanding beyond exercise programming as client demand for longevity and GLP-1 guidance reshapes the profession.
The study reveals numerous benefits of an integrated care model that combines weight-loss drugs with exercise, especially strength training.
Members are no longer satisfied with fitness alone. They are coming into facilities with a different set of expectations — ones shaped as much by healthcare as by traditional gym experiences. They want personalization that goes beyond a training routine, a clearer understanding of what is happening inside their bodies, and a sense that their...
Early clinical trial results show that apitegromab dramatically reduced lean mass loss in people taking tirzepatide, the main ingredient in Mounjaro.
People taking GLP-1s are more likely to join a gym and exercise than they were just a year ago, according to findings from William Blair Equity Research.
Life Time Q1 revenue rose 11.7% and CEO Bahram Akradi calls GLP-1 weight-loss drugs "a home run" for the fitness industry.
Sign Up to Our Newsletter
